MedTrace Logo

Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

NCT06190158 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2025-04-09

No results posted yet for this study

Summary

The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.

Conditions

Interventions

DIAGNOSTIC_TEST

Oral sodium suppression test

Oral sodium suppression test (\~2 grams of supplemental sodium for 3 days)

DIAGNOSTIC_TEST

Saline suppression test

Saline suppression test (2 liters of saline)

DIAGNOSTIC_TEST

Captopril suppression test

Captopril suppression test (50mg of captopril)

DIAGNOSTIC_TEST

Dexamethasone suppression test

1mg of dexamethasone

DIAGNOSTIC_TEST

Cosyntropin stimulation test

250mcg of cosyntropin

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2029-07-31
Completion
2029-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06190158 on ClinicalTrials.gov